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Abstract
Background: Existing epidemiological studies of the association between oxidative stress and erectile dysfunction
(ED) are sparse and inconclusive, which is likely due to cross-sectional design and small sample size. Therefore, we
investigated the association between biomarkers of oxidative stress and ED in prospective setting among a
relatively large sample size of men.
Methods: We conducted the prospective study among 917 men ages between 47 and 80 years at the time of
blood draw, which is a part of nested prospective case–control study of prostate cancer in the Health Professionals
Follow-up Study. Plasma fluorescent oxidation products (FlOPs), a global biomarker for oxidative stress, were
measured at three excitation/emission wavelengths (360/420 nm named as FlOP_360; 320/420 nm named as
FlOP_320 and 400/475 nm named as FlOP_400).
Results: Approximately 35 % of men developed ED during follow-up. We did not find an independent association
between FlOP_360, FlOP_320, FlOP_400 and risk of ED in the multivariable adjusted model (Tertile 3 vs. tertile 1: odds
ratio [OR] = 0.90, 95 % confidence interval [CI] = 0.61-1.34, Ptrend = 0.54 for FlOP_360; OR = 0.73, 95 % CI = 0.49-1.07,
Ptrend = 0.27 for FlOP_320; and OR = 0.98, 95 % CI = 0.66-1.45, Ptrend = 0.72 for FlOP_400). Further analysis of the
association between FlOPs and ED in the fasting samples or controls only (free of prostate cancer incidence)
did not change the results appreciably.
Conclusions: Plasma FlOPs were not associated with the risk of ED, suggesting oxidative stress may not be an
independent risk factor for ED.
Background
Oxidative stress reflects an imbalance between systemic
levels of reactive oxygen species (ROSs) and host antioxi-
dant defense systems that are able to counteract (detoxify)
these ROSs. Insufficient antioxidant defense systems against
ROSs can result in damage to proteins, lipids and DNA in
cells and organs in humans. High level of oxidative stress is
an important risk factor for many prevalent diseases includ-
ing cardiovascular disease, breast cancer and reduced renal
function [1–3].
The level of plasma fluorescent oxidation products
(FlOPs) is a reliable and convenient approach to assess
circulating oxidative stress in large epidemiological stud-
ies. One advantage of this marker as compared to other
traditional specific oxidation markers (i.e., F2-isoprostanes
and malondialdehyde) is that FLOP assay reflects oxidation
pathways from multiple sources including lipid, protein and
DNA [4, 5], whereas traditional specific oxidation markers
reflect only a portion of oxidative stress. In large observa-
tional studies, we found that the level of plasma FlOPs is
increased with hypertension, smoking and reduced renal
function as defined by reduced levels of glomerular filtra-
tion rate [1, 3, 5, 6]. Furthermore, we have documented
that the FlOP assay is robust in epidemiologic and clinical
setting in which the collection and processing of blood
samples cannot be well-controlled. We have found that
FlOPs are stable in the blood samples with delayed pro-
cessing up to 48 h at 4 °C, stable for more than 10 years
in plasma samples in liquid-nitrogen freezers, and
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highly reproducible over 1–2 year among the same in-
dividuals [5, 7].
The association between oxidative stress and erectile
dysfunction (ED) is sparse and inconclusive, which is likely
due to cross-sectional design and small sample size. It is
well known that oxidative stress plays an important role in
the development of atherosclerotic diseases [8, 9]. Athero-
sclerosis reduces cavernosal blood flow, leading to vascu-
logenic ED [10, 11]. However, existing epidemiological
studies of the association between oxidative stress and ED
either had small sample size (N ≤ 60) or were cross-
sectional [12–14]. Further, none of above studies adjusted
for important potential confounders such as diabetes,
hypertension and cigarette smoking which are the risk fac-
tors for ED and are important determinants of oxidative
stress [5, 15, 16]. Large and prospective studies are war-
ranted to examine the independent relationship between
oxidative stress and ED. Therefore, we investigated the
association between plasma FlOPs and ED in prospective
settings among a relatively large sample size of men.
Methods
Study participants and blood collection
The Health Professionals Follow-up Study (HPFS) initiated
in 1986 is an ongoing prospective study of 51,529 men.
Between 1993 and 1995, blood collection kits were sent to
participants and 18,140 men returned specimens on ice by
using an overnight courier. All returned blood samples
were processed within 36 h after blood draw and stored in
liquid nitrogen freezers. Based on the participants who
donated blood samples, a 1:1 matched nested prospective
case–control study of prostate cancer was performed from
the time of blood draw [17]. All participants were free of
diagnosed cardiovascular diseases and cancers at the time
of blood draw. After excluding the ineligible participants
(Fig. 1), we finally included 917 men ages between 47 and
80 years (median = 62 years) at the time of blood draw in
the prospective study. Among 917 men, 457 and 460 men
were subsequent incident prostate cancer cases and con-
trols, respectively. Written informed consent was obtained
from all participants. This investigation was approved by
Institutional Review Board of the Brigham and Women’s




We measured plasma FlOPs using previously described
procedures [5]. In brief, plasma was extracted with etha-
nol/ether (3:1, v/v) and centrifuged to obtain supernatant.
We measured fluorescence of the supernatant at three
wavelengths (360/420 nm [excitation/emission] named as
FlOP_360, 320/420 nm named as FlOP_320 and 400/
475 nm named as FlOP_400). FlOP_360 represents the
interaction between lipid oxidation products and proteins,
DNA and carbohydrates. FlOP_320 can be produced when
oxidation products such as lipid hydroperoxides, alde-
hydes, and ketones react with DNA in the presence of
metals, and FlOP_360 reflects the interaction between
malondialdehyde, proteins and phospholipids [18]. The
Fig. 1 Flowchart of the participants excluded from the nested prospective case–control study of prostate cancer in the Health Professional
Follow-up Study 1993–2001
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within-run average coefficient of variations for FlOP mea-
surements were < 13 %.
Assay stability in blood samples with delayed processing
All blood samples were processed within 36 h after receiv-
ing the samples. The delay in processing blood samples up
to 36 h appeared to have minimal influence on the meas-
urement of FlOPs. The overall intraclass correlation
coefficients (ICCs) of FlOPs were all greater than 0.95
in the shorter- (0 to 24 h) and longer-delayed process-
ing (0 to 36 h) [7].
Assay between- and within- person reproducibility
We conducted a pilot study in 40 participants who donated
two blood samples from the Nurse Health Study. After
adjusting for fasting status, the ICC of the between- and
within- person variations of the FlOPs for repeated mea-
surements over 1.4 year apart (range: 0.8-2.2 years) was
0.44 for FlOP_360, 0.55 for FlOP_320, and 0.70 for
FlOP_400 [3].
ED Ascertainment
Between 2000 and 2001, a recall questionnaire in HPFS
participants was initiated to rate their ability to have and
maintain an erection sufficient for sexual intercourse. The
question was “Please rate your ability (without treatment)
to have and maintain an erection good enough for inter-
course for the following time periods:”. Time periods in-
cluded “before 1986”, “1986-1989”, “1990-1994”, “1995 or
later” and “in the last 3 months”. Responses of the ques-
tionnaire included “very poor”, “poor”, “fair”, “good” and
“very good”. ED was defined if participants answered “very
poor” or “poor”. Any ED cases ascertained clearly after
blood draw (1993–1995) were considered incident ED. If
year of blood draw and year of ED ascertainment may be
overlapping (i.e., year of blood draw was 1995 and period
of ED ascertainment was ‘1995 or later’), these ED cases
were not defined as incident ED. If the ED cases were not
defined as incidence above, these ED cases were used in
the cross-sectional analysis only (Fig. 1). Regardless ED
cases recovered at a later time or not, they were defined as
ED cases in the current study. Whether these cases were
included in the cross-sectional or prospective analysis was
dependent on the time period of ED ascertainment.
Statistical analyses
To make a comprehensive understanding on relationship
between plasma FlOPs and ED, we performed both
prospective and cross-sectional analysis (Fig. 1). In the
prospective analysis, we analyzed the association between
plasma FlOPs and incidence of ED with logistic regression
model, but not with Cox proportional hazard model as we
were not exactly sure the year of incident EDThe risk of
incident ED in lowest tertile of FlOPs was compared with
that in the second and third tertile of FlOPs. The covariates
included in the prospective analysis were age (continuous),
body mass index (BMI, continuous), alcohol intake (in
quartiles: < 0.9, ≥ 0.9 and < 6.6, ≥ 6.6 and < 17.2, ≥ 17.2
g/day), physical activity (in quartiles: < 13.85, ≥ 13.85
and < 28.9, ≥ 28.9 and < 51.95, ≥ 51.95 MET-hours/
week), Caucasian (yes/no), fasting hours (continuous),
benign prostatic hyperplasia with surgery (yes/no), his-
tory of hypertension (yes/no), history of diabetes (yes/no),
smoking status (current smokers, past smokers and non-
smokers), month of blood draw (in seasons: Spring
[March, April and May], Summer [June, July and August],
Fall [September, October and November], Winter
[December, January and February]) and year of blood
draw (1993, 1994 and 1995). To further rule out the po-
tential confounding by fasting status and subclinical fac-
tors of prostate cancer incidence, we also examined the
association between FlOPs and ED in fasting samples and
controls only (free of prostate cancer incidence), respect-
ively. In the cross-sectional analysis, we examined the as-
sociation between plasma FlOPs and ED at baseline with
logistic regression model. The covariates included in the
cross-sectional analysis were same as the prospective ana-
lysis. All analyses were performed with Statistical Analysis
System (Version 9, SAS Institute Inc., Cary, NC).
Results
Baseline characteristics according to plasma FlOP levels
In the prospective analysis, higher levels of plasma
FlOP_360, FlOP_320 and FlOP_400 were associated with
older age, greater alcohol intake, lower proportion of men
who had fasted ≥ 8 h before blood draw and great propor-
tion of current and past smokers (Table 1). Higher levels
of FlOP_360 were correlated with greater proportion of
history of hypertension. Higher levels of FlOP_400 were
correlated with greater BMI. When similar analysis was
performed in prostate cancer cases and controls separ-
ately, the relationship between baseline characteristics and
FlOPs in either group was similar to that in the overall
samples (Additional file 1: Table S1 and Additional file 2:
Table S2). Moreover, the relationship between baseline
characteristics in propective analysis (Table 1) was com-
parable to that in cross-sectional analysis (Additional
file 3: Table S3).
Association between plasma FlOPs and ED
In the prospective analysis, 35 % (N = 323) of men were
identified having incident ED after blood draw. Although
the proportion of incident ED appeared to be higher
among men with higher levels of FlOPs (Table 2), we did
not find an independent association between FlOP_360,
FlOP_320, FlOP_400 and risk of ED in the multivariable
adjusted model (Tertile 3 vs. tertile 1: OR = 0.90, 95 %
CI = 0.61-1.34, Ptrend = 0.54 for FlOP_360; OR = 0.73,
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95 % CI = 0.49-1.07, Ptrend = 0.27 for FlOP_320; and
OR= 0.98, 95 % CI = 0.66-1.45, Ptrend = 0.72 for FlOP_400).
Further analysis of the association between FlOPs and
ED in the fasting samples (≥ 8 h) did not change the re-
sults appreciably (Tertile 3 vs. tertile 1: OR = 0.91, 95 %
CI = 0.56-1.47, Ptrend = 0.69 for FlOP_360; OR = 0.75, 95 %
CI = 0.46-1.21, Ptrend = 0.52 for FlOP_320; and OR = 0.83,
95 % CI = 0.51-1.35, Ptrend = 0.53 for FlOP_400).
When we analyzed the relationship between plasma
FlOPs and risk of ED in controls only (free of prostate
cancer incidence), levels of FlOP_360, FlOP_320 and
FlOP_400 were again not associated with increased risk
of ED (Table 3).
In the cross-sectional analysis, we found 3.7 % (N = 37) of
men with ED at the time of blood draw. Higher levels of
FlOP_360 were associated with increased risk of baseline
ED (Tertile 3 vs. tertile 1: odds ratio [OR] = 2.68, 95 %
confidence interval [CI] = 1.01-7.12), and the relationship
had a significant trend (Ptrend = 0.03). However, higher
levels of FlOP_320 and FlOP_400 were not associated with
baseline ED (Additional file 4: Table S4).
Discussion
To our knowledge, this is the first study that comprehen-
sively assessed the association between oxidative stress
and ED in both prospective and cross-sectional designs.
Although higher levels of FlOP_360 were associated with
increased risk of ED in the cross-sectional design, none of
FlOP_360, FlOP_320 or FlOP_400 was associated with in-
cidence of ED in the prospective design. Since the
relationship between biomarkers of oxidative stress and
ED is largely derived from animal models [10], the results
of our study have challenged the traditional understand-
ings on the independent detrimental effects of oxidative
stress on ED in human.
We only found FlOP_360, but not FlOP_320 or
FlOP_400, was positively associated with ED in cross-
sectional design. Several reasons may be responsible: First,
we cannot fully exclude a possibility of false-positive
findings due to the fact that cross-sectional analysis had a
small number of ED cases (N = 37) and only one type of
FlOPs (FlOP_360 only) was associated with ED. Second,
because of the cross-sectional design, the positive relation-
ship between FlOP_360 and ED in cross-sectional design
may be due to ED-related diseases that are correlated with
oxidative stress. Certainly, further studies are warranted to
confirm this.
In contrast to the positive association between
FlOP_360 and ED in the cross-sectional study, we did
not show consistent evidence of a positive association be-
tween oxidative stress and risk of ED in the prospective
design, which had approximately 9 times as many cases as
cross-sectional analysis. Besides the much larger number
of cases, the prospective design limited reverse causation.
However, it is possible that the underlying mechanism of
oxidative stress on ED was not due to a global oxidative
burden but a specific type of ROSs. There is animal and
tissue evidence suggesting that superoxide with nitric
oxide can result in acute impairment of cavernosal relax-
ation but also long-term penile vasculopathy [19–21].
Table 1 Baseline characteristics according to tertiles of plasma fluorescent oxidation products (FlOPs) (N = 917): prospective analysis
in the Health Professional Follow-up Study, 1993-1995
Variables FlOP_360 FlOP_320 FlOP_400
Tertile 1 2 3 1 2 3 1 2 3
Range (FI/ml) < 184 ≥ 184; < 233 ≥ 233 < 356 ≥ 356; < 524 ≥ 524 < 49.1 ≥ 49.1; < 62.6 ≥ 62.6
N 305 306 306 305 306 306 305 306 306
Age (years) 61.1 61.9 62.3 60.4 62.2 62.6 60.7 62.3 62.2
Body mass index (kg/m2) 25.8 25.8 25.7 25.5 25.9 25.9 25.4 25.9 26.0
Alcohol intake (g/day)a 2.9 8.2 10.0 3.5 8.8 8.6 2.4 8.2 10.4
Physical activity (MET-hours/week)a 26.0 33.6 29.1 27.9 34.2 26.5 28.3 29.8 28.1
Caucasians (%) 92 92 95 91 95 93 93 91 95
Fasting status (≥ 8 h; %) 76.4 56.2 50.3 75.7 56.5 50.7 71.2 59.5 52.3
History of BPH with surgery (%) 1.6 3.6 3.3 1.3 3.3 3.9 2.0 3.6 2.9
History of hypertension (%) 23.3 23.9 31.4 20.3 30.4 27.8 21.3 31.1 26.1
History of diabetes (%) 3.6 2.6 2.9 2.6 3.3 3.3 2.3 3.9 2.9
Current smokers (%) 1.1 6.7 13.0 1.1 9.6 9.4 1.1 4.2 16.5
Past smokers (%) 37.8 49.8 60.8 38.6 55.4 54.4 35.1 50.9 62.7
Variables with normal distribution are shown in mean, unless otherwise specified
aVariables with skew distribution are shown in median
Abbreviations: FlOP = Fluorescent oxidation products, FI = Fluorescent intensity unites, MET =Metabolic equivalent, BPH = Benign prostatic hyperplasia
Bold-faced values indicate statistically significance at P < 0.05 across tertiles of FlOPs
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The study has several limitations. First, a single measure-
ment of FlOPs may not accurately reflect the average levels
of the biomarker over a prolonged period of time. However,
we have assessed their reproducibility over approximately a
one-year period, and high ICCs suggest that this marker
can be used as a marker for chronic exposure. Second,
since we only ascertained ED via a single self-reported
questionnaire on ED onset during approximately 7 years
after blood draw, we cannot exclude the recall bias as a
possible explanation of our results. Furthermore, our
assessment of ED has not been validated; however, we note
that a prior report using these data [22] were consistent
with what has been found in other studies [15, 23]. None-
theless, these two methodological weaknesses regarding the
ascertainment of ED may lead to misclassification between
incident ED and healthy controls. Third, our study is
limited because the specific oxidative stress level at penile
site was not available. Fourth, as our study only included
history of BPH with surgery, some BPH cases with less se-
vere clinical conditions might not be included. Fifth, the
bias due to other known (i.e., duration of hypertension and
smoking) or unknown residual confounding factors that are
related to plasma FlOPs and ED is likely present. Sixth, our
study was derived from another study designed to study
prostate cancer but not ED. The sampling of that nested
case–control study may introduce biases that affected our
study and may limit the generation of our results. All the
above limitations may cause the null association between
plasma FlOPs and incident ED.
The strength of the study is that it contained relatively
large sample size of men and incident EDs. In addition,
as mentioned above, the prospective study design is a
better design than cross-sectional design to reduce the
possibility of the reverse causation between oxidative
stress and ED, although an effect of subclinical disease
on biomarkers cannot be excluded.
Table 2 Association between plasma fluorescent oxidation products (FlOPs) and erectile dysfunction in prostate cancer cases
(N =457) and controls (N = 460): prospective analysis in the Health Professional Follow-up Study, 1993-2001
Tertile 1 2 3 P for trend
Variables FlOP_360
Range (FI/ml) < 184 ≥ 184; < 233 ≥ 233 —
N 305 306 306 —
Median (FI/ml) 160 207 280 —
Erectile dysfunction incidence
(n, %)
100 (33 %) 112 (37 %) 111 (36 %) —
Age adjusted 1 (ref) 1.13 (0.79, 1.61) 1.07 (0.75, 1.52) 0.84
Multivariable adjusteda 1 (ref) 1.03 (0.71, 1.51) 0.90 (0.61, 1.34) 0.54
FlOP_320
Range (FI/ml) < 356 ≥ 356; < 524 ≥ 524 —
N 305 306 306 —
Median (FI/ml) 302 410 1837 —
Erectile dysfunction incidence
(n, %)
102 (33 %) 114 (37 %) 107 (35 %) —
Age adjusted 1 (ref) 1.00 (0.70, 1.42) 0.86 (0.60, 1.23) 0.30
Multivariable adjusteda 1 (ref) 0.75 (0.51, 1.11) 0.73 (0.49, 1.07) 0.27
FlOP_400
Range (FI/ml) < 49.1 ≥ 49.1; < 62.6 ≥ 62.6 —
N 305 306 306 —
Median (FI/ml) 44.0 55.1 72.6 —
Erectile dysfunction incidence
(n, %)
100 (33 %) 99 (32 %) 124 (41 %) —
Age adjusted 1 (ref) 0.82 (0.57, 1.17) 1.24 (0.87, 1.77) 0.14
Multivariable adjusteda 1 (ref) 0.67 (0.45, 0.99) 0.98 (0.66, 1.45) 0.72
Values are odds ratio (95 % confidence interval), unless otherwise specified. FI = Fluorescent intensity units
aRisk factors include age (continuous), body mass index (continuous), alcohol intake (in quartiles: < 0.88, ≥ 0.88 and < 5.58, ≥ 5.58 and < 16.38, ≥ 16.38 g/day),
physical activity (in quartiles: < 15.6, ≥ 15.6and < 30.6, ≥ 30.6 and < 56.9, ≥ 56.9 MET-hours/week), Caucasian (yes/no), fasting hours (continuous), benign prostatic
hyperplasia with surgery (yes/no), history of hypertension (yes/no), history of diabetes (yes/no), smoking status (current smokers, past smokers and non-smokers),
month of blood draw (in seasons: Spring [March, April and May], Summer [June, July and August], Fall [September, October and November], Winter [December,
January and February]) and year of blood draw (1993, 1994 and 1995)
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Conclusions
In conclusion, we found no overall association between
plasma FlOPs and risk of ED. This has raised an important
message that systemic oxidative stress markers overall may
not be a relevant measure for assessing the risk of incident
ED. Therefore, the necessity of oxidative stress measure-
ment in the risk of ED assessment is questionable. Since
this is the first prospective study on biomarkers of global
oxidation only, further investigation of other biomarkers of
oxidative stress in relation to ED is warranted.
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